Xi has represented a wide range of multinational companies, Chinese state-owned enterprises and private companies on various aspects of competition law, including handling Chinese and overseas merger filings, responding to investigations, devising compliance programmes and providing behavioural counselling. Xi has a wealth of experience in various sectors including healthcare, automotive, industrial, FMCG, oil & gas, technology & internet, and infrastructure & transport and fund investment.
Xi is qualified in the PRC and the New York State of the US. Prior to joining Zhao Sheng, he worked at leading international law firms including working at the offices in Brussels and London.
Xi was ranked by Chambers and Partners as an “Up and Coming” Lawyer and named a “Future Leader – Competition” by Who’s Who Legal. He is also regularly recognised as a “Rising Star” by Euromoney and won the Best Antitrust Writing Awards by Concurrences.
CSR Corporation Limited and China CNR Corporation Limited on the multijurisdictional merger filings for their $26 billion merger of equals
China National Nuclear Corporation on the multijurisdictional merger filings for the acquisition of China Nuclear Engineering & Construction Group Corporation Limited
China Merchants Port Holdings on the Chinese merger filing for the acquisition into Liaoning Port Group
Jingye Group on the multijurisdictional merger filings for its acquisition of certain assets of British Steel, the UK’s second-largest steelmaker
Takeda on the Chinese merger clearance in relation to its $62 billion acquisition of Shire, the biggest ever overseas acquisition by a Japanese company
SABMiller on the conditional Chinese merger clearance in relation to its £71 billion acquisition by AB InBev
Qiagen on the Chinese merger filing for its $12.5 billion contemplated but aborted acquisition by Thermo Fisher Scientific
Consortium led by GIP and Meridiam on the Chinese merger clearance for its $15.44 billion acquisition of certain businesses in relation to the Veolia/Suez transaction
Bayer on the Chinese merger clearance for its $7.6 billion sale of animal health business to Elanco, creating the world’s second-biggest animal-health company.
Reckitt Benckiser on the Chinese merger clearance for its $16.6 billion acquisition of Mead Johnson
Glencore on the remedy implementation for the conditional Chinese merger clearance in relation to its acquisition of Xstrata
2011 - 2012 New York University School of Law (Vanderbilt Scholar), LL.M
2006 - 2008 Renmin University of China, LL.M
2002 - 2006 Renmin University of China, LL.B